These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34224797)

  • 1. Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells.
    Lee JM; Shin KS; Koh CH; Song B; Jeon I; Park MH; Kim BS; Chung Y; Kang CY
    Cancer Lett; 2021 Nov; 520():38-47. PubMed ID: 34224797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of CD11c⁺ cells in the CD11c.DTR model drives expansion of unique CD64⁺ Ly6C⁺ monocytes that are poised to release TNF-α.
    Sivakumaran S; Henderson S; Ward S; Sousa PS; Manzo T; Zhang L; Conlan T; Means TK; D'Aveni M; Hermine O; Rubio MT; Chakraverty R; Bennett CL
    Eur J Immunol; 2016 Jan; 46(1):192-203. PubMed ID: 26464217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed vaccine-induced CD8
    van der Sluis TC; van Haften FJ; van Duikeren S; Pardieck IN; de Graaf JF; Vleeshouwers W; van der Maaden K; Melief CJM; van der Burg SH; Arens R
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response.
    Liang X; Li L; Li X; He T; Gong S; Zhu S; Zhang M; Wu Q; Gong C
    Theranostics; 2021; 11(14):6936-6949. PubMed ID: 34093863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report:
    Huang JW; Kuo CL; Wang LT; Ma KS; Huang WY; Liu FC; Yang KD; Yang BH
    Front Immunol; 2021; 12():752563. PubMed ID: 35003064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells.
    Pinho MP; Sundarasetty BS; Bergami-Santos PC; Steponavicius-Cruz K; Ferreira AK; Stripecke R; Barbuto JA
    Cytotherapy; 2016 Apr; 18(4):570-80. PubMed ID: 26971685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells.
    Trojandt S; Knies D; Pektor S; Ritz S; Mailänder V; Grabbe S; Reske-Kunz AB; Bros M
    Cancer Immunol Immunother; 2013 Aug; 62(8):1315-26. PubMed ID: 23666509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity.
    Kitai Y; Kawasaki T; Sueyoshi T; Kobiyama K; Ishii KJ; Zou J; Akira S; Matsuda T; Kawai T
    J Immunol; 2017 Feb; 198(4):1649-1659. PubMed ID: 28069806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.
    Wang HY; Wang RF
    Adv Immunol; 2012; 114():151-76. PubMed ID: 22449781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.
    Garris CS; Luke JJ
    Clin Cancer Res; 2020 Aug; 26(15):3901-3907. PubMed ID: 32332013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.
    Fecek RJ; Storkus WJ
    Immunotherapy; 2016 Oct; 8(10):1205-18. PubMed ID: 27605069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-glucan from Aureobasidium pullulans augments the anti-tumor immune responses through activated tumor-associated dendritic cells.
    Shui Y; Hu X; Hirano H; Kusano K; Tsukamoto H; Li M; Hasumi K; Guo WZ; Li XK
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108265. PubMed ID: 34715491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs.
    Truxova I; Pokorna K; Kloudova K; Partlova S; Spisek R; Fucikova J
    Immunol Lett; 2014 Jul; 160(1):39-49. PubMed ID: 24726860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.
    McKenzie JA; Mbofung RM; Malu S; Zhang M; Ashkin E; Devi S; Williams L; Tieu T; Peng W; Pradeep S; Xu C; Zorro Manrique S; Liu C; Huang L; Chen Y; Forget MA; Haymaker C; Bernatchez C; Satani N; Muller F; Roszik J; Kalra A; Heffernan T; Sood A; Hu J; Amaria R; Davis RE; Hwu P
    J Natl Cancer Inst; 2018 Jul; 110(7):777-786. PubMed ID: 29267866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment.
    Chang MC; Chen YL; Lin HW; Chiang YC; Chang CF; Hsieh SF; Chen CA; Sun WZ; Cheng WF
    Mol Ther; 2018 Feb; 26(2):404-419. PubMed ID: 29248428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma.
    Wildes TJ; Grippin A; Dyson KA; Wummer BM; Damiani DJ; Abraham RS; Flores CT; Mitchell DA
    Clin Cancer Res; 2018 Aug; 24(16):3955-3966. PubMed ID: 29712687
    [No Abstract]   [Full Text] [Related]  

  • 18. Empowering dendritic cell cancer vaccination: the role of combinatorial strategies.
    Galati D; Zanotta S
    Cytotherapy; 2018 Nov; 20(11):1309-1323. PubMed ID: 30360963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
    Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
    J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.